An observational study in Intracranial Arterial Stenosis and Brain Diseases, sponsored by The Affiliated Hospital of Qingdao University. Recruiting at 1 site in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-01-20.
Sponsored by The Affiliated Hospital of Qingdao University · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 41 studies in Brain Diseases with a site in China — 18 open to participants now, 19 under way, 1 of them phase 3. Brain Diseases · China.
Among the 41 studies in Brain Diseases with a site in China, this one is the 10th largest by planned enrollment of the 13 observational ones that give a count, is one of 8 that started in 2025, is one of 13 observational ones, reaches primary completion later than 11 of the 18 other live ones, and was the 41st registered.
502 studies on the registry are indexed under Brain Diseases; 141 are open to participants now.
Browse Brain Diseases studies →18 of the 41 studies in Brain Diseases with a site in China are open now. Recruiting first, the newest first:
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
Duan Chuanzhi · Sites in China
Xuanwu Hospital, Beijing · Sites in China
Ages 18+
Xiangya Hospital of Central South University · Sites in China
Healthy volunteers
The Second Hospital of Anhui Medical University · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 109 Brain Diseases studies recruiting now, 53 (49%) set no upper age limit and 22 (20%) stop at 75 or younger; 18 take children under 18; 22 take healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
41 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 8 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 149 across 144 observational studies indexed under Brain Diseases.
Median enrollment 229 across the 28 interventional studies, 600 across the 13 observational. Of the 13 that completed or were terminated, 4 (31%) have results posted.
This tab as a report to print or save as PDF → With an account.
11 of 41 have an industry lead sponsor. The 10 most frequent:
The Affiliated Hospital of Qingdao University is the lead sponsor of 151 studies on the registry; 56 are open to participants now.
The Affiliated Hospital of Qingdao University has 1 study filed under Brain Diseases — fewer than ten, so there is no comparison to draw.
2 of the studies in Brain Diseases with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06633809Sir Run Run Shaw HospitalTherapy Evaluation in Patients With Minor Stroke and Large Vessel Occlusion | 2026-12-31 |
| NCT07187687Xuanwu Hospital, BeijingTrIal of Early Minimally Invasive Catheter Evacuation With Thrombolysis in IntraCerebral Hemorrhage | 2027-09-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 41 studies in Brain Diseases with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
This clinical trial is a prospective, multicenter, single-arm study. About 300 subjects undergoing rapamycin-eluting stent implantation will be enrolled based on the inclusion and exclusion criteria. The primary endpoint is the rate of any stroke or death within 1 month. Secondary efficacy endpoints include immediate stent implantation success. Safety endpoints cover the incidence of stroke or neurological death, target-vessel-related stroke or death, all-cause mortality, and mRS scores at 12-month follow-ups. Subjects will be clinically followed up before surgery, device implantation, discharge, and at 1, 6, and 12 months post-surgery. An imaging subgroup of at least 80 subjects who agree to DSA follow-up at 12 months will assess in-stent restenosis (>50%).
subjects undergoing rapamycin-eluting stent implantation
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
subjects undergoing rapamycin-eluting stent implantation
Incidence of any stroke or death within 1 month after the procedure
Time frame: 1 month
Incidence of in-stent restenosis (stenosis degree >50%) at 1year (imaging subgroup)
Time frame: 1 year
Immediate techenical success rate of stent implantation (imaging subgroup)
Time frame: immediately after the intervention
Incidence of stroke or neurogenic death within 1-year follow-up
Time frame: 1 year
Incidence of target vessel-related stroke or death within 1-year follow-up
Time frame: 1 year
All-cause mortality within 1-year follow-up
Time frame: 1 year
mRS score at 1-year follow-up
mRS≥2
Time frame: 1 year
Plan to share: Undecided
No publications or documents are linked to this record.
Started May 2025 (actual). Primary completion is estimated for Dec 2027, 31 months after the start.
Of 80 non-industry observational studies under Brain Diseases, half reached primary completion within 62 months of starting (the median), counting those still running; a quarter within 23 and three quarters within 193. This study's planned 31 months is below that.
Counting every sponsor, half of 89 studies reached it within 62 months; a quarter within 23 and three quarters within 193.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
The Affiliated Hospital of Qingdao University →